Human Cell Line Production of Recombinant Factor VII
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant blood coagulation factor VII face challenges such as incomplete γ-carboxylation and inefficient removal of propeptide, leading to suboptimal functional recovery in cell culture medium, particularly for therapeutic use in treating hemophilia patients with inhibitory antibodies against factor VIII and IX.
Innovation Solution
The use of human cell lines modified with a lentiviral vector containing FVII cDNA, combined with optimized cultivation conditions, including the suppression of calumenine gene expression and overexpression of VKORC1, to enhance γ-carboxylation and production of biologically active rFVII, avoiding immunogenic epitopes expressed in murine cells and improving post-translational modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce recombinant factor VII in cell culture, then production can be achieved, but γ-carboxylation is incomplete and propeptide removal is inefficient, leading to suboptimal functional recovery
Solution Approach 1:
The patent changes the biological parameters of the production system by switching from murine cell lines to human cell lines (HEK293, HepG2, Sk-Hep1), which naturally possess the appropriate enzymatic machinery for complete γ-carboxylation of factor VII. This parameter change in cell line origin resolves the incomplete carboxylation issue while maintaining high productivity
Solution Approach 2:
The patent introduces lentiviral vectors as intermediaries to deliver the factor VII gene into human cell lines. The viral vector system serves as a mediator that enables efficient gene transfer and stable expression, thereby achieving both complete γ-carboxylation and high functional recovery simultaneously
2Productivity
If murine cell lines are used for production, then production can be achieved, but immunogenic epitopes are expressed that may cause immune responses in patients
Solution Approach 1:
The patent changes the species origin parameter of the production cells from murine to human. By using human cell lines (HEK293, HepG2, Sk-Hep1), the produced factor VII lacks murine-specific immunogenic epitopes, eliminating the risk of immune responses while maintaining high production capacity
3Object-affected harmful factors
If human cell lines are used instead of murine lines, then immunogenic safety is improved and post-translational modifications are enhanced, but the complexity of modifying and optimizing cell lines increases
Solution Approach 1:
The patent uses lentiviral vectors as intermediaries to simplify the modification of human cell lines. The viral delivery system provides efficient and stable gene integration, reducing the operational complexity compared to traditional transfection methods while enabling the use of human cell lines for safe and effective factor VII production
Data Source
AI summary
A process for producing blood coagulation Factor VII in large scale in 3 human cell lines (HepG2, Sk-Hep, and HKB-11) and to select the best recombinant protein producer is described. The murine line BHK-21 was used as control. The data allowed for the assertion that the system used to modify cell lines was efficient, so that all the cells were satisfactorily modified, and produced the protein of interest in a stable form. In addition, when comparing the murine line BHK-21 with the human cells (HepG2, Sk-Hep-1 and HKB-11), the latter proved to be able to produce rFVII more efficiently, which allows us to conclude that human cell lines are a great alternative to produce recombinant blood coagulation factors in large scale.